JP2023535073A5 - - Google Patents
Info
- Publication number
- JP2023535073A5 JP2023535073A5 JP2023504634A JP2023504634A JP2023535073A5 JP 2023535073 A5 JP2023535073 A5 JP 2023535073A5 JP 2023504634 A JP2023504634 A JP 2023504634A JP 2023504634 A JP2023504634 A JP 2023504634A JP 2023535073 A5 JP2023535073 A5 JP 2023535073A5
- Authority
- JP
- Japan
- Prior art keywords
- complex according
- exon
- antibody
- oligonucleotide
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055777P | 2020-07-23 | 2020-07-23 | |
| US63/055,777 | 2020-07-23 | ||
| US202063069077P | 2020-08-23 | 2020-08-23 | |
| US63/069,077 | 2020-08-23 | ||
| US202163143829P | 2021-01-30 | 2021-01-30 | |
| US63/143,829 | 2021-01-30 | ||
| PCT/US2021/040998 WO2022020107A1 (en) | 2020-07-23 | 2021-07-09 | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023535073A JP2023535073A (ja) | 2023-08-15 |
| JP2023535073A5 true JP2023535073A5 (enExample) | 2024-07-18 |
| JP7803926B2 JP7803926B2 (ja) | 2026-01-21 |
Family
ID=79728346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504634A Active JP7803926B2 (ja) | 2020-07-23 | 2021-07-09 | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230285586A1 (enExample) |
| EP (1) | EP4185330A4 (enExample) |
| JP (1) | JP7803926B2 (enExample) |
| KR (1) | KR20230044242A (enExample) |
| CN (1) | CN116368150A (enExample) |
| AU (1) | AU2021312709A1 (enExample) |
| BR (1) | BR112023001125A2 (enExample) |
| CA (1) | CA3186752A1 (enExample) |
| IL (1) | IL299662A (enExample) |
| MX (1) | MX2023000984A (enExample) |
| WO (1) | WO2022020107A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2020219820A1 (en) | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| CN116194470B (zh) * | 2020-07-23 | 2025-10-03 | 达因疗法公司 | 肌肉靶向复合物及其用途 |
| IL303332A (en) * | 2020-12-04 | 2023-07-01 | Dyne Therapeutics Inc | Antibody-oligonucleotide complexes and their uses |
| WO2022270585A1 (ja) | 2021-06-23 | 2022-12-29 | 日本新薬株式会社 | アンチセンスオリゴマーの組み合わせ |
| AU2022309238A1 (en) * | 2021-07-09 | 2024-01-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| JP2024527362A (ja) * | 2021-07-09 | 2024-07-24 | ダイン セラピューティクス，インコーポレーテッド | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
| JP2024525608A (ja) * | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| JP2024525611A (ja) * | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| JP2024525612A (ja) * | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| KR20240035823A (ko) * | 2021-07-09 | 2024-03-18 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도 |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| EP4702143A2 (en) | 2023-04-24 | 2026-03-04 | BioMarin Pharmaceutical Inc. | Compositions and methods for treating stxbp1 disorders |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8734799B2 (en) * | 2010-04-13 | 2014-05-27 | The Regents Of The University Of California | Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer |
| BR112013014527A2 (pt) * | 2010-12-20 | 2017-03-07 | Genentech Inc | anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina |
| PE20170256A1 (es) * | 2014-01-24 | 2017-04-22 | Ngm Biopharmaceuticals Inc | Proteinas de union y sus metodos de uso |
| EA039366B1 (ru) * | 2015-06-24 | 2022-01-19 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер |
| FR3049951A1 (fr) | 2016-04-12 | 2017-10-13 | Univ Rabelais Francois | Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose |
| MX2020003130A (es) * | 2017-09-22 | 2020-09-25 | Avidity Biosciences Inc | Composiciones y metodos de induccion de salto de exon en acidos nucleicos-polipeptidos. |
| TWI869346B (zh) * | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| CA3108282A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2020028842A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy |
| GB2595980B (en) * | 2019-01-04 | 2023-06-14 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| JP7780691B2 (ja) * | 2020-01-10 | 2025-12-05 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| KR20230041760A (ko) * | 2020-07-23 | 2023-03-24 | 다인 세라퓨틱스, 인크. | 항-트랜스페린 수용체 (tfr) 항체 및 그의 용도 |
| CN116194470B (zh) * | 2020-07-23 | 2025-10-03 | 达因疗法公司 | 肌肉靶向复合物及其用途 |
-
2021
- 2021-07-09 MX MX2023000984A patent/MX2023000984A/es unknown
- 2021-07-09 AU AU2021312709A patent/AU2021312709A1/en active Pending
- 2021-07-09 EP EP21846687.8A patent/EP4185330A4/en active Pending
- 2021-07-09 IL IL299662A patent/IL299662A/en unknown
- 2021-07-09 US US18/017,179 patent/US20230285586A1/en active Pending
- 2021-07-09 CA CA3186752A patent/CA3186752A1/en active Pending
- 2021-07-09 BR BR112023001125A patent/BR112023001125A2/pt unknown
- 2021-07-09 CN CN202180064570.5A patent/CN116368150A/zh active Pending
- 2021-07-09 JP JP2023504634A patent/JP7803926B2/ja active Active
- 2021-07-09 KR KR1020237005853A patent/KR20230044242A/ko active Pending
- 2021-07-09 WO PCT/US2021/040998 patent/WO2022020107A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023535073A5 (enExample) | ||
| JP2023510350A5 (enExample) | ||
| JP2024527362A5 (enExample) | ||
| JP2021532831A5 (enExample) | ||
| JP2021533197A5 (enExample) | ||
| JP2023512441A5 (enExample) | ||
| JP2021533199A5 (enExample) | ||
| JP2024525610A5 (enExample) | ||
| JP2021533198A5 (enExample) | ||
| JP2023535078A5 (enExample) | ||
| JP2024525611A5 (enExample) | ||
| JP2023509793A5 (enExample) | ||
| JP2021533200A5 (enExample) | ||
| Schlake et al. | mRNA as novel technology for passive immunotherapy | |
| JP2021532832A5 (enExample) | ||
| JP2024525613A5 (enExample) | ||
| JP2023512442A5 (enExample) | ||
| JP2024160045A5 (enExample) | ||
| JP2024525612A5 (enExample) | ||
| IL309937A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309909A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2025067909A5 (enExample) | ||
| JP2023510351A5 (enExample) | ||
| IL309935A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2024524222A5 (enExample) |